Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check CVNA chart recent major squeeze. Had 50%+ of float shorted before that major move.. NVAX should do really well considering FDA green lights them
How high could this go during the short squeeze? Have you seen other stocks in this position regarding shorts? With such a high percentage of shares shorted, and with the new Covid vaccine relatively close to FDA approval, seems pretty risky to short this stock right now.
I took advantage of the sell-off/shorting today to buy shares under $9.
42% float short…announcement…then the “mother of all squeezes”
Nvax becomes #1 shorted stock in the markets
(.) - (.)
\/
———-
Eyes on nvax squeeze !
https://www.highshortinterest.com
$8.55 squeeze !!!
Watch for $8.50 break here for vol push !
$8.40 Short Squeeze Watch ~ 8/29/23
42%+ Of Float Short 39+ Mill Shares Pending Vaccine News -> https://finviz.com/quote.ashx?t=NVAX&p=d
Pending news !!—> Novavax is in the process of submitting applications for its XBB.1.5 COVID vaccine candidate to regulatory authorities globally.
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
Source: PR Newswire (US)
Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3
Upon regulatory approval, Novavax's COVID vaccine would be the only protein-based non-mRNA vaccine option available in key markets for the fall season
GAITHERSBURG, Md., Aug. 22, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies. XBB sublineage variants are overwhelmingly responsible for the majority of current COVID cases in the U.S. and European Union.1, 2
"Our data have shown that Novavax's protein-based COVID vaccine induces broadly neutralizing responses against XBB subvariants, including EG.5.1 and XBB.1.16.6," said Filip Dubovsky, President of Research and Development, Novavax. "We have a lot of confidence in our updated COVID vaccine and are working diligently with global regulatory bodies to ensure our protein-based vaccine is available this fall."
Non-clinical data previously showed that Novavax's COVID vaccine candidate induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants, indicating a broad response that could potentially be applicable for forward-drift variants.3 Novavax is in the process of submitting applications for its XBB.1.5 COVID vaccine candidate to regulatory authorities globally.
has anybody seen yesterday where enzolytics pharm announced they now have a cure for hiv/aids. wow.
NVAX
Novavax Inc
7.4089
-0.2811 (-3.66%)
Volume: 6,408,571
Day Range: 7.34 - 7.73
Last Trade Time: 7:59:23 PM EDT
NVAX
Novavax Inc
8.61
-0.63 (-6.82%)
Volume: 5,536,007
Day Range: 8.51 - 9.2277
Bid: 8.55
Ask: 8.67
Last Trade Time: 7:57:52 PM EDT
Total Trades: 34,562
NO LIKE DIS STUFF <> $NVAX <> raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.
Novovax – which has its COVID-19 vaccine as the only marketed product after 35 years in business – has raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.
The company said in May it expects 2023 revenue between $1.4 billion and $1.6 billion, of which $800 million was from "locked-in" overseas purchase contracts for the COVID shot that it has committed to ship this year.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta Agarwal)
NO LIKE DIS STUFF <> $NVAX <> raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.
Novovax – which has its COVID-19 vaccine as the only marketed product after 35 years in business – has raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.
The company said in May it expects 2023 revenue between $1.4 billion and $1.6 billion, of which $800 million was from "locked-in" overseas purchase contracts for the COVID shot that it has committed to ship this year.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta Agarwal)
[-chart]www.stockscores.com/chart.asp?TickerSymbol=NVAX&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
[-chart]www.stockscores.com/chart.asp?TickerSymbol=NVAX&TimeRange=1825&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
NVAX
Novavax Inc
9.57
-0.05 (-0.52%)
Volume: 2,592,837
Day Range: 9.49 - 9.9198
Bid: 9.57
Ask: 9.58
Last Trade Time: 12:47:59 PM EDT
Total Trades: 18,700
KIND OF BULLISH OF LATE
$NVAX NEWS Reuters Fri, July 7, 2023 at 6:17 PM EDT
IRONICALLY 1MIN BEFORE YOU POSTED THIS
$NVAX ????? FLOUNDERING DOWN SINCE $500 DOLLARS <>
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172299699
Novavax to receive $350 mln from Canada for unused COVID shots
https://finance.yahoo.com/news/novavax-receive-350-mln-canada-221754182.html
CONGRATS ANYONE MAKING $$$
NVAX
Novavax Inc
7.29
0.23 (3.26%)
Volume: 3,209,243
Day Range: 7.05 - 7.3399
Last Trade Time: 7:59:57 PM EDT
$NVAX ????? FLOUNDERING DOWN SINCE $500 DOLLARS <>
NVAX
Novavax Inc
6.73
-0.43 (-6.01%)
Volume: 16,355,553
Day Range: 6.61 - 7.14
Last Trade Time: 7:59:52 PM EDT
YES, BACK TO SQUARE ONE AFTER NO PRODUCT SHOWED UP $nvax
NVAX
Novavax Inc
6.73
-0.43 (-6.01%)
Volume: 16,355,553
Day Range: 6.61 - 7.14
Last Trade Time: 7:59:52 PM EDT
NVAX
Novavax Inc
7.15
0.26 (3.77%)
Volume: 4,104,111
Day Range: 6.795 - 7.265
Last Trade Time: 7:59:42 PM EDT
So many bagholders with $200/share averages.
thanks for your wonderful words...
I am glad I got in here at 7.13.... however, like all of us, I should have bought more.... lol
NVAX
Novavax Inc
7.5675
-0.1025 (-1.34%)
Volume: 264,535
Day Range: 7.54 - 7.71
Bid: 7.56
Ask: 7.57
Last Trade Time: 10:05:15 AM EDT
Total Trades: 1,763
Thanks for your updates.... I'm dipping my toes in here...
BACK TO SQUARE ONE WE STARTED HERE WHEN COVID-19 HIT AMERICA
NVAX
Novavax Inc
7.67
0.11 (1.46%)
Volume: 3,450,580
Day Range: 7.33 - 7.765
Last Trade Time: 7:54:09 PM EDT
NVAX
Novavax Inc
7.67
0.11 (1.46%)
Volume: 3,450,580
Day Range: 7.33 - 7.765
Last Trade Time: 7:54:09 PM EDT
NVAX
Novavax Inc
9.16
-0.36 (-3.78%)
Volume: 3,979,041
Day Range: 9.01 - 9.535
Last Trade Time: 7:59:53 PM EDT
Still more boom to run up .
Is that still your view?
Another company will benefit tremendously from the pipeline. Who will be buying?
Welcome! They said within a Year so who knows. We could all be dead in a year lol.
Thanks, I had missed that
You didn’t read their News yesterday? They said they expect to not be able to run their business soon.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8525
|
Created
|
06/19/03
|
Type
|
Free
|
Moderators mick JoeForkeyBolo |
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Using innovative proprietary recombinant nanoparticle vaccine technology,
we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. More...
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease. More...
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |